La vendita allo scoperto per Mainz Biomed dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Mainz Biomed. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Mainz Biomed (NASDAQ:MYNZ) Azioni, Report sulle vendite allo scoperto

Mainz Biomed

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Mainz Biomed NV

<a href="https://www.benzinga.com/personal-finance/25/03/44380108/trust-me-im-reading-what-hes-doing-every-day-nba-legend-shaq-with-a-500-million-net-worth-swears-by-warren-buffetts-investing-wisdom">Shaquille O'Neal</a> might have a net worth floating around half a billion dollars, but even he'll tell you — money smarts weren't always part of the game plan. In fact, it took one simple piece of advice, delivered courtside and <a href="https://www.benzinga.com/personal-finance/25/04/44634785/magic-johnson-is-worth-billions-but-he-says-you-cant-get-there-thinking-only-about-yourself">straight from Magic Johnson</a>, to flip the script.
"When I first got to L.A., [Johnson] said, ‘Shaq, it's okay to be famous and all that, but at some point, you want to start owning things,'" O'Neal told Daymond John of "Shark Tank" during the <a href="https://www.youtube.com/live/z5ZjtU70Oms?si=YLaMqmxBx7AmalRK">2020 Black Entrepreneurs Day event</a>.
That wasn't just locker room wisdom — it was a turning point.&nbsp;
Don't Miss:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>
Shaq, who famously torched his first million-dollar check on flashy cars and jewelry, admits he didn't know the first thing about taxes, saving, or investing when he was drafted. Even after signing a $40 million deal with the Orlando Magic, the financial lightbulb hadn't gone off. That came later — with Magic.
And let's talk about that Magic.
In 2023, <a href="https://www.forbes.com/profile/magic-johnson/">Forbes officially named Johnson a billionaire</a>, making him just the fourth athlete in history to earn the title, alongside Michael Jordan, Tiger Woods, and LeBron James. But Johnson didn't get there by clinging to basketball contracts. He made his name in the business world — buying into Starbucks before most athletes were thinking about branding, and later owning major stakes in the Dodgers, Sparks, Los Angeles FC, and the Washington Commanders.
Shaq saw all that in real time. The glitz of NBA stardom was great — but what Johnson had? That was different. That was long-term.
Trending: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
So <a href="https://www.benzinga.com/personal-finance/25/03/44171160/nba-legend-shaq-says-krispy-kreme-is-his-favorite-franchise-investment-and-his-reason-is-incredibly-simple-cause-i-like-doughnuts">Shaq got to work</a>. After retiring in 2011, he didn't just license his name — he built an empire. Today, he's got stakes in everything from Papa John's to car washes to fitness centers, and he claims to earn more annually in retirement than he ever did as a player. He even went back to school, picking up an MBA and later a doctorate in education, all while absorbing lessons from real business owners, TV investors, and yes, still watching "Shark Tank" for good measure.
"I'm still learning now," Shaq told John. "I watch ‘Shark Tank' and I learn from you guys. I love to ask questions."
For anyone who still thinks being an athlete and being an entrepreneur live in separate arenas, Magic and Shaq have been proving them wrong for decades. One gave the advice. The other turned it into action.
Being famous pays. But owning things? That's what builds empires.
Read Next:
<ul>
<li>The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a></li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>

Personal Finance

Shaq Says Billionaire Magic Johnson Gave Him the 'Best' Money Advice — Being Famous Is Cool, 'But at Some Point, You Want to Start Owning Things'

BofA Securities analysts Bryan D. Spillane, Lisa K. Lewandowski and Peter T. Galbo have put forward on Tuesday their research findings on consumer staple companies in the face of a potential recession.
The analysts said consumer staples have historically outperformed the S&amp;P 500 in most recent recessions, suggesting a defensive edge.
However, the analysts warned that current conditions, such as lingering high prices and weak volume growth, may limit their resilience in a future downturn.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/25/04/44695622/amazon-touts-ai-milestone-says-new-model-outshines-gpt-4o-in-real-time-speech" rel="noreferrer noopener">Amazon Touts AI Milestone, Says New Model Outshines GPT-4o In Real-Time Speech</a>
Still, their limited exposure to new tariffs could make the sector more appealing than others, potentially helping sustain valuation multiples.
During recessions, the Consumer Staples sector stock prices are primarily influenced by earnings per share (EPS) rather than sales growth.
Analysis shows that forward EPS estimates account for over 90% of stock price movement across key subsectors like Beverages, Household &amp; Personal Care (HPC), Packaged Food, and Tobacco, with the correlation being the tightest Beverages and HPC.
The analysts noted that this highlights the critical importance of earnings strength when evaluating stock performance in uncertain economic conditions.
A review of six past recessions reveals that certain Consumer Staples stocks consistently outperformed the S&amp;P 500.
Campbell Soup Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>), Colgate-Palmolive Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), General Mills Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>), McCormick &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>), PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>), and Hormel Foods Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRL#NYSE">HRL</a>) each posted a 100% success rate in outperforming the index during those downturns.
In the last four recessions with the most comprehensive data, McCormick, General Mills, and Church &amp; Dwight Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) delivered the strongest relative performance.
Top-performing Consumer Staples stocks in a potential downturn will likely share three traits: profit flexibility to offset revenue pressure and rising costs, strong U.S. manufacturing presence to limit tariff-related inflation, and solid balance sheets capable of sustaining share buybacks to boost earnings per share.
Analysts see McCormick, Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) and Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) as well-defended, with Keurig Dr Pepper Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>), Molson Coors Beverage Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) and Altria Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) in the next tier of potential outperformers.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44685643/whats-going-on-with-rocket-lab-stock-today-4" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Rocket Lab Stock Today?</a></li>
</ul>
Image via Shutterstock

Analyst Color

Analyst Ratings

Trading Ideas

This Beverage Maker, Tobacco Company And Packaged Food Giant Outshine In A Recession

President Donald Trump&#8217;s tariff announcements led to a sell-off in the stock market and prompted investors to move to safer assets such as Treasury bonds. The 10-year Treasury yield declined and the average 30-year fixed mortgage rate dropped from 6.75% to<a href="https://www.benzinga.com/news/25/04/44695176/president-trump-is-fixing-america-grant-cardone-says-wants-you-to-invest-in-real-estate-invest-in-america"> 6.55% last week. </a>
Mortgage Rates: Despite the initial drop, mortgage rates rebounded as Treasury yields ticked back up. On Monday, the 30-year fixed-rate mortgage surged to 6.82%, marking the largest single-day increase of the year.&nbsp;
The current rate for a 30-year fixed mortgage sits at 6.85%, <a href="https://www.mortgagenewsdaily.com/markets/mortgage-rates-04082025">according</a> to Mortgage News Daily.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/04/44695907/elon-musk-calls-trump-trade-advisor-peter-navarro-dumber-than-sack-of-bricks-defends-tesla-as-the-most-american-made-cars">Elon Musk Calls Trump Trade Advisor Peter Navarro &#8216;Dumber Than Sack Of Bricks,&#8217; Defends Tesla As &#8216;Most American-Made Cars&#8217;&nbsp;</a>
Home Sales: Pending home sales ticked higher in early April with 72,000 newly pending single-family home sales and 15,000 condo transactions last week — the highest weekly volume since late April 2024, <a href="https://www.nar.realtor/research-and-statistics">according</a> to the National Association of Realtors. 
"Despite the modest monthly increase, contract signings remain well below normal historical levels," said Lawrence Yun, NAR's chief economist.&nbsp;
"A meaningful decline in mortgage rates would help both demand and supply — demand by boosting affordability and supply by lessening the power of the mortgage rate lock-in effect."
Buyer Demand: Recent mortgage rate stability encouraged buyers, with purchase applications reaching their highest growth rate since late 2023 in early April. However, Trump's new tariff policies and China's retaliation have reintroduced uncertainty and volatility to the stock market and mortgage rates. 
"The spring housing season is beginning with more sellers and a growing number of homes for sale," said Danielle Hale, chief economist at Realtor.com.
"But the high cost of buying coupled with growing economic concerns suggest a sluggish response from buyers in early spring," Hale added.&nbsp;
<h1 class="wp-block-heading">Inventory and Pricing Trends</h1>
<ul>
<li>Inventory Growth: Unsold inventory now stands at 691,000 single-family homes, 34.75% above 2024 levels, though Northeastern markets remain tight, <a href="https://blog.altosresearch.com/weekly-pending-home-sales-are-finally-above-last-year">according</a> to Altos Research.</li>
<li>Price Pressures: Median pending sale prices reached $397,500, just 0.25% higher than 2024. Eight states — including Texas, Florida, and Arizona — show slight year-over-year declines, signaling localized cooling.</li>
<li>Price Reductions: The number of homes on the market with price reductions ticked up in the first week of April to 34.3%. </li>
</ul>
Real Estate ETF: Investors can find alternative exposure to the real estate market through the Vanguard Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNQ#NYSE">VNQ</a>), which tracks the MSCI US Investable Market Real Estate 25/50 Index, measuring the performance of U.S. equity REITs, specialized REITs and real estate management/development companies. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44537429/cathie-wood-doubles-down-on-2600-tesla-stock-price-prediction">Cathie Wood Doubles Down On $2,600 Tesla Stock Price Prediction</a></li>
</ul>
Image: Shutterstock

News

REIT

Specialty ETFs

Treasuries

Markets

ETFs

Real Estate

Tariff Turmoil Sends Mortgage Rates Higher, 'Contract Signings Remain Well Below Normal Historical Levels'

Scotiabank analyst Konark Gupta maintains Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Sector Outperform and raises the price target from $255 to $260.

Price Target

Scotiabank Maintains Sector Outperform on Waste Management, Raises Price Target to $260

Scotiabank analyst Konark Gupta maintains Secure Waste Infr (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SES#TSX">SES</a>) with a Sector Outperform and lowers the price target from C$22 to C$19.5.

TSX:SES

Scotiabank Maintains Sector Outperform on Secure Waste Infr, Lowers Price Target to C$19.5

Scotiabank analyst Konark Gupta maintains Republic Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) with a Sector Perform and raises the price target from $233 to $250.

Scotiabank Maintains Sector Perform on Republic Servs, Raises Price Target to $250

Scotiabank analyst Konark Gupta maintains GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) with a Sector Outperform and raises the price target from $52 to $54.

Scotiabank Maintains Sector Outperform on GFL Environmental, Raises Price Target to $54

Scotiabank analyst Maher Yaghi maintains Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) with a Sector Perform and raises the price target from $48 to $48.5.

Scotiabank Maintains Sector Perform on Verizon Communications, Raises Price Target to $48.5

Scotiabank analyst Maher Yaghi maintains AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) with a Sector Outperform and raises the price target from $28.5 to $29.

Scotiabank Maintains Sector Outperform on AT&T, Raises Price Target to $29

Scotiabank analyst Maher Yaghi maintains Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Sector Perform and raises the price target from $44.5 to $45.

CMCSA

Scotiabank Maintains Sector Perform on Comcast, Raises Price Target to $45

Scotiabank analyst Eric Winmill maintains New Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NGD#AMEX">NGD</a>) with a Sector Outperform and raises the price target from $4 to $4.25.

Scotiabank Maintains Sector Outperform on New Gold, Raises Price Target to $4.25

Wells Fargo analyst Roger Read maintains Shell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) with a Overweight and lowers the price target from $87 to $83.

SHEL

Wells Fargo Maintains Overweight on Shell, Lowers Price Target to $83

Wells Fargo analyst Michael Brown maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Overweight and lowers the price target from $93 to $87.

SCHW

Wells Fargo Maintains Overweight on Charles Schwab, Lowers Price Target to $87

Wells Fargo analyst Michael Brown maintains Stifel Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>) with a Overweight and lowers the price target from $135 to $106.

Wells Fargo Maintains Overweight on Stifel Financial, Lowers Price Target to $106

Wells Fargo analyst Michael Brown maintains Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) with a Equal-Weight and lowers the price target from $176 to $143.

Wells Fargo Maintains Equal-Weight on Raymond James Finl, Lowers Price Target to $143

Wells Fargo analyst Michael Brown maintains Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) with a Equal-Weight and lowers the price target from $63 to $55.

Wells Fargo Maintains Equal-Weight on Moelis, Lowers Price Target to $55

Wells Fargo analyst Michael Brown maintains LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) with a Overweight and lowers the price target from $405 to $342.

LPLA

Wells Fargo Maintains Overweight on LPL Finl Hldgs, Lowers Price Target to $342

A federal judge on Tuesday ordered the White House to temporarily lift access restrictions it imposed on the Associated Press, pending the outcome of a lawsuit filed by the news organization.
The restrictions, in place since Feb. 11, had barred AP reporters from Oval Office events, Air Force One flights and other official functions, <a href="https://www.washingtonpost.com/style/media/2025/04/08/associated-press-white-house-ban-lifted/">reported </a>the Washington Post.
The dispute centers on the White House's demand that the AP use the term "Gulf of America" rather than "Gulf of Mexico" in its coverage. The AP declined, citing editorial independence, and filed a lawsuit on Feb. 21 against three Trump administration officials, claiming viewpoint discrimination.
U.S. District Judge Trevor N. McFadden sided with the AP, ruling that the government cannot exclude journalists from press events based on their editorial decisions. While the judge delayed enforcement of the ruling for five days to allow for administrative response, he was clear in his stance.
"If the Government opens its doors to some journalists… it cannot then shut those doors to other journalists because of their viewpoints," McFadden wrote. "The Constitution requires no less."
McFadden found the AP likely to succeed on the merits of its First Amendment claims. Testimony from AP's chief photographer and White House correspondent described how the ban hindered the organization's competitiveness and slowed its news gathering — concerns the judge deemed credible.
He also criticized the administration's "brazen" justification for the ban, rooted in the AP's continued use of "Gulf of Mexico."
AP spokesperson Lauren Easton praised the ruling, calling it a victory for press freedom. "Today's ruling affirms the fundamental right of the press and public to speak freely without government retaliation," she said.
The White House has not issued a response as of publication Tuesday. 
Read Next: <a href="https://www.benzinga.com/government/regulations/25/04/44701436/trump-unleashes-beautiful-clean-coal-policies-as-wall-street-tanks-sp-500-hits-1-year-low"> • Trump Unleashes &#8216;Beautiful Clean Coal&#8217; Policies As Wall Street Tanks, S&amp;P 500 Hits 1-Year Low</a>
Photo: T.Schneider via Shutterstock

Government

Legal

Media

Judge Orders White House To Lift Ban On Associated Press Access

Wells Fargo analyst Michael Brown maintains Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) with a Equal-Weight and lowers the price target from $44 to $38.

Wells Fargo Maintains Equal-Weight on Lazard, Lowers Price Target to $38

Wells Fargo analyst Michael Brown maintains Houlihan Lokey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLI#NYSE">HLI</a>) with a Overweight and lowers the price target from $179 to $170.

Wells Fargo Maintains Overweight on Houlihan Lokey, Lowers Price Target to $170

Health Care

Press Releases

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

General

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Mainz Biomed Expands into Switzerland with labor team w

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Earnings

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

MYNZ

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Ainos

Alzamend Neuro

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aprea Therapeutics

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Geovax Labs

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Ocean Biomedical

PharmaCyte Biotech

Portage Biotech

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Soligenix

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

Maxim Group

JonesTrading

Screenshot 2025-04-02 at 9.29.30 PM

Biotech

Mainz BioMed&#39;s Trial To Bring Critical Early Cancer Detection One Step Closer

Screenshot 2024-12-19 at 7.13.05 PM

Screenshot 2024-11-21 at 6.41.48 PM

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test

Screenshot 2024-11-12 at 8.43.58 PM

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening

Comments

Mainz Biomed

Vendite allo scoperto

Mainz Biomed (NASDAQ:MYNZ) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO